Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation

NCT: NCT07470788 · RECRUITING

NCT IDNCT07470788
StatusRECRUITING
Start Date2026-08
Completion2032-04
SponsorVesalius Cardiovascular Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This first-in-human study evaluates the safety and performance of the Vesalius Transcatheter Mitral Valve Repair (TMVr) System in patients with degenerative mitral regurgitation. The study will enroll patients who are at high or prohibitive risk for conventional surgical repair or replacement of the mitral valve. Participants will receive implantation of the Vesalius TMVr System and will be followed to assess clinical outcomes, device performance, and any adverse events.

Frequently Asked Questions

What is FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation?

FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation is a clinical trial registered under NCT07470788. Current status: RECRUITING.

What is the status of NCT07470788?

The current status of NCT07470788 (FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation) is: RECRUITING.

When did FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation start?

FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation started on 2026-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.